Proteins and Peptides
14 November 2013
Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog13 November 2013
NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex® (Teduglutide [rDNA origin]) for Injection13 November 2013
Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A13 November 2013
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Chronic Idiopathic Constipation13 November 2013
Discovery Labs Receives FDA Clearance of IND to Initiate AEROSURF® Phase 2 Clinical Program11 November 2013
ERYTECH Announces Positive DSMB Review of its Phase IIb Study in Acute Myeloid Leukemia11 November 2013
Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH8 November 2013
Santarus and Pharming Announce New Data from Open-Label Repeat Treatment Study with RUCONEST (Recombinant Human C1 Esterase Inhibitor)7 November 2013
Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia4 November 2013
Allegro Ophthalmics Announces Commencement of First Human Subject Study with ALG-1001 to Treat Vitreomacular Traction4 November 2013
Alfact Innovation Announces Positive Clinical Trial Results for Treatment of AIH- and HBV- Related Acute-on-Chronic Liver Diseases1 November 2013
Completion of a “First in Human” Clinical Phase I Study with a Therapeutic Protein Derived from CAP® Cells31 October 2013
Baxter Submits Application for European Approval of RIXUBIS, Recombinant Factor IX (nonacog gamma) for Hemophilia B30 October 2013
The Medicines Company’s EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints29 October 2013
Sophiris Announces First Patients Dosed in the “PLUS-1” Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia29 October 2013
Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease28 October 2013
Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma25 October 2013
NPS Pharmaceuticals Submits Biologic License Application to the U.S. Food and Drug Administration for Natpara® in Hypoparathyroidism23 October 2013
Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticum23 October 2013
Polaris Group Files New IND for ADI-PEG 20 in Breast CancerNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports